Anticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 1, 2003, Pages

  McCrory, Douglas C ^a   Brown, Cynthia D ^b  

^a DUKE UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122913201     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003900     Document Type: Review

References (54)

1. Backman R, Hellstrom PE. Fenoterol and ipratropium in respiratory treatment of patients with chronic bronchitis. Current Therapeutic Research, Clinical and Experimental 1985;38(1):135-40.
2. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Annals of Emergency Medicine 1995;25(4):470-3.
3. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98(4):835-9.
4. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. European Respiratory Journal 1988;1:536-9.
5. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50(8):834-7.
6. O'Driscoll BR, Taylor RJ, Horsley MG, Chambers DK, Bernstein A. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989;1(8652):1418-20.
7. Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990;98(2):295-7.
8. Rebuck AS, Chapman KR, Abboud R, Pare PD, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. The American Journal of Medicine 1987;82:59-64.
9. Shrestha M, O'Brien T, Haddox R, Gourlay HS, Reed G. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Annals of Emergency Medicine 1991;20(11):1206-9.
10. Alabaster VA. Discovery and development of selective M3 antagonists for clinical use. Life Sciences 1997;Vol 60(13-14):1053-60.
11. Anonymous. Bronchodilation for COPD?. Emergency Medicine 1992;24(11):62.
12. Anonymous. Combivent. Hospital Formulary 1997;32(2):119.
13. Anonymous. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest 1997;112(6):1514-21.
14. Anzueto A, Kesten S. Effects of tiotropium in COPD patients only treated with PRN albuterol [Abstract]. American Thoracic Society 100th International Conference, May 21-26, Orlando. 2004:C47, Poster F81.
15. Arsovki Z, Dokic D, Boskovska M, Goseva Z, Kaeva B, Gliugorovski L, et al. The effect of combined B2-agonist and anticholinergic inhaled therapy in patients with COPD [Abstract]. European Respiratory Journal 2004;24(Suppl 48):341s.
16. Balkinssoon RC, Murphy JR, Make B. Safety and efficacy of albuterol vs aulbuterol/ipratropium bromide in COPD subjects on fluticasone/salmeterol 500/50 [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:Poster F8.
17. Bleecker ER, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. The American Journal of Medicine 1991;91(4A):24A-27S. [MEDLINE: 92059092]
18. Blosser SA, Maxwell SL, Reeves-Hoche MK, Localio AR, Zwillich CW. Is an anticholinergic agent superior to a beta2-agonist in improving dyspnea and exercise limitation in COPD?. Chest 1995;108(3):730-5.
19. Celikel S, Yilmaz A, Seyfikli Z, Etikan I. Evaluation of bronchodiltor response to single dose tiotropium bromide [Abstract]. European Respiratory Journal 2004;24(Suppl 48):504s.
20. Chapman KR. The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease. Lung 1990;168(Suppl):295-303. [MEDLINE: 90348303]
21. de Guia T, Punzal P, Canizares L, Sy-Naval S, Salonga R, Tan D, et al. Evaluation of the response of Filipino COPD patients to Tiotropium (EVEREST STUDY) [Abstract]. American Thoracic Society 100th International Conference, May 21-26; Orlando. 2004:Poster F78.
22. Dejaegher P, Demedts M, Rochette F, Van der Veken J. Effects of 40 mcg. and 400 mcg. of ipratropium bromide in obstructive lung disease. Acta Clinica Belgica 1984;39(3):136-40. [MEDLINE: 85019143]
23. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (spiriva(TM)): Mechanistical considerations and clinical profile in obstructive lung disease. Life Sciences 1999;64(6-7):457-64.
24. Dusser D, Bravo ML, Iacono P. Tiotropium reduces health resource utilization associated with COPD exacerbations [Abstract]. European Respiratory Journal 2004;24(Suppl 48):513s.
25. Dusser D, Bravo ML, Iacono P, MISTRAL Study Group. Tiotropium reduces COPD exacerbations: the MISTRAL study. European Respiratory Journal 2004;24(Suppl 48):513s.
26. Fernandez A, Muñoz J, de la Calle B, Alia I, Ezpeleta A, de la Cal MA, et al. Comparison of one versus two bronchodilators in ventilated COPD patients. Intensive Care Medicine 1994;20:199-202. [MEDLINE: 94284401; EMBASE 94097968]
27. Gross NJ, Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease. Comparison with a beta-adrenergic agent. American Review of Respiratory Disease 1987;136(5):1091-4. [MEDLINE: 88047665]
28. Ikeda A, Nishimura K, Izumi T. Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease. Drugs & Aging 1998;12(2):129-37.
29. Kalberg C, Emmett A, Bourne E, Merchant K, Knobil K. Fluticasone propionate/salmeterol provides greater relief of dyspnea than Ipratropium/Albuterol in patients with COPD [Abstract]. American Thoracic Society 100th International Conference, May 21-26; Orlando. 2004:Poster 528.
30. Limauro J, Mahler DA, Olmstead EM, Tosteson ANA. Responses to inhaled bronchodilator in patients with acute airflow obstruction. Respiratory Care 1995;40(8):815-9. [EMBASE 1995258156]
31. Lode H. Inhalational anticholinergic versus inhaled beta-mimetic drugs in COPD. Internist 1999;40(1):114.
32. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998;352(9126):467-73.
33. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respiratory Medicine 1996;90(8):497-9.
34. Miravitlles M, Murio C, Guerrero T, Segu JL. Treatment of chronic bronchitis and chronic pulmonary obstructive disease in primary care. Archivos de bronchopneumologia 1999;35(4):173-8. [MEDLINE: 99260797]
35. Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Respiratory Medicine 1999;93(3):173-9. [MEDLINE: 99394140]
36. Musil J, Hirsch V, Vondra V, Reisova M. Dosage of drugs in combined nebulisation therapy of patients with chronic obstructive pulmonary disease (COPD). Studia Pneumologica et Phtiseologica 1998;57(6):257-9.
37. Musil J, Hirsch V, Vondra V, Reisova M. What is the adequate dose in combined inhalation treatment of patients with exacerbations of chronic obstructive pulmonary disease?. Vnitrni Lekarstvi 1998;44(7):415-7.
38. Nair S, Thomas E, Pearson SB, Henry MT. A randomized controlled trial to assess the optimal dose and effect of nebulized albuterol in acute exacerbations of COPD. Chest 2005;128(1):48-54.
39. Nakanishi N, Ueda N, Kitade M, Moritaka T, Kamei T. Effects of oxitropium bromide on exercise and lung function in patients with pulmonary emphysema. Japanese Journal of Thoracic Diseases. 1997;35(1):38-42.
40. Nardini S. Inhaled antimuscarinic agents and COPD. Monaldi Archives for Chest Disease 1996;51(1):52-3.
41. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine 1996;154(4 Pt 1):876-80. [MEDLINE: 97042378]
42. Rees PJ. Bronchodilators in the therapy of chronic obstructive pulmonary disease. European Respiratory Monograph 1998;3(7):135-49.
43. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest 1996;110(1):62-70.
44. Rennard SI. Choice of bronchodilator therapy in chronic obstructive pulmonary disease. Respirology 1997;2(Suppl 1):S11-5.
45. Sabradillo PV. The outpatient and hospital use of anticholinergics in COPD. Archivos De Bronconeumologia 1997;33(Suppl 2):34-9.
46. Sawa T, Yasuda N, Gotoh K, et al. Effect of additional high dose inhalation of oxitropium bromide on respiratory function in the patients with COPD. Therapeutic Research 1997;18(3):389-95.
47. Shioya T, Kagaya M, Sano M, Itaba M, Shindo T, Miura M. Antimuscarinic effect of tiquizium bromide in vitro and in vivo. European Journal of Clinical Pharmacology 1996;50(5):375-80.
48. Tashkin D, Celli B, Decramer M, Pauwels R, Menjoge S, Burkhart D, et al. Bronchodilator responsiveness in COPD patients enrolled in the UPLIFT trial [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:Poster J102.
49. Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. European Respiratory Journal 1996;9(1):100-3.
50. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987;106(2):196-204. [MEDLINE: 87098280; EMBASE 87077377]
51. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1995;152(5 (Pt 2)):S77-121. [MEDLINE: 96048961]
52. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [MEDLINE: 96308458]
53. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. American Review of Respiratory Disease 1992;146(4):1067-83. [MEDLINE: 93036759]
54. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. European Respiratory Journal 1995;8(8):1398-420. [MEDLINE: 96087552]